Key result
Combined biomarker models predict iliac vein stent restenosis with a pooled AUC up to ~0.84.
Why the study?
Iliac vein stent restenosis remains a significant complication following stent placement for iliac vein compression syndrome and post-thrombotic syndrome.
Does biomarker screening and timed intervention improve the prediction and management of iliac vein stent restenosis in patients post-stenting?
Systematic Review (n=127)
Does biomarker screening and timed intervention improve the prediction and management of iliac vein stent restenosis in patients post-stenting?
Biomarker models show promise for predicting iliac vein stent restenosis, but prospective trials are urgently needed to define optimal intervention timing and validate these tools for clinical use.
Answers are grounded in this paper and cite their sources.
May enhance post-iliac stent surveillance; leaves open clinical adoption pending prospective validation.
Iliac vein stent restenosis (ISR) remains a significant complication following stent placement for iliac vein compression syndrome (Rajput et al. in Cardiovasc Diagn Ther. 11:1103–1115, 2021) and post-thrombotic syndrome, with reported 1-year incidence rates of 18%-30%. This systematic review synthesizes evidence from the past five years to evaluate advances in predictive biomarker discovery, the concept of an optimal intervention window, and emerging therapeutic strategies. A comprehensive literature search identified 127 relevant studies. Our analysis reveals that combined biomarker models incorporating inflammatory cytokines (e.g., IL-6), microRNA panels (e.g., miR-92a/126), and coagulation-fibrosis markers (e.g., TAT, TGF-β1) show promising predictive value (pooled AUC up to 0.84), though clinical validation remains limited. Pathophysiological and computational modeling suggests a critical "subclinical stenosis phase" may exist 3-6 months post-stenting, during which interventions might be more effective, but robust clinical trial data supporting specific timing is scarce. While drug-eluting stents reduce short-term ISR rates, long-term safety concerns persist. Novel approaches, including bioresorbable materials and targeted biological therapies, are primarily in preclinical stages. This review underscores the urgent need for standardized biomarker validation, prospective trials to define intervention timing, and interdisciplinary collaboration to translate mechanistic insights into improved clinical outcomes for ISR prevention and management.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a systematic review in Iliac vein stent restenosis (ISR) (n=127). Combined biomarker models (inflammatory cytokines, microRNAs, coagulation-fibrosis markers) vs. Standard surveillance was evaluated on Predictive value for iliac vein stent restenosis (pooled AUC up to 0.84). Combined biomarker models incorporating inflammatory cytokines, microRNAs, and coagulation-fibrosis markers show promising predictive value for iliac vein stent restenosis with a pooled AUC up to 0.84.
Synapse has enriched 10 related papers. Consider them for comparative context: